rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Autolus Therapeutics plc - American Depositary Shares

AUTL · Nasdaq

Health CareBiotechnologyJust dropped out

AUTL stood above a rising 150-day average in 19 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 6.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Just dropped out
Weeks in an uptrend
out for 1
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$31K
Officials’ trades on record
0
Institutions holding
80 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$30K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
Cintia PiccinaU.S. CCO & Country Gen Managersold6,713at $2.342 Sep 2026filed 3 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders80+0 on the quarter
New · exited9 · 9
Reported value$211.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
MAK CAPITAL ONE LLCunchanged · filed 14 Aug 202633,621,487$53.8M00.0%
Blackstone Inc.unchanged · filed 14 Aug 202620,485,611$32.8M00.0%
Syncona Portfolio Ltdunchanged · filed 7 Aug 202616,640,720$26.6M00.0%
ARMISTICE CAPITAL, LLCreduced · filed 14 Aug 202615,000,000$24.0M-800,000−5.1%
Tetragon Partners GP Ltdunchanged · filed 13 Aug 20269,500,000$15.2M00.0%
SCHRODER INVESTMENT MANAGEMENT GROUPreduced · filed 13 Aug 20267,833,282$12.9M-1,656,063−17.5%
Frazier Life Sciences Management, L.P.unchanged · filed 14 Aug 20264,447,910$7.1M00.0%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.unchanged · filed 13 Aug 20263,361,156$5.4M00.0%
Laurion Capital Management LPunchanged · filed 13 Aug 20263,316,626$5.3M00.0%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 20261,984,700$3.2M-314,799−13.7%
31 Mar 2023 – 30 Jun 2026
5882105Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Cintia Piccina Company insiderU.S. CCO & Country Gen Manager · last 2 Sep 20260 · 1
Cynthia M. Butitta Company insiderDirector · last 29 Jun 20260 · 0
Elisabeth Leiderman Company insiderDirector · last 29 Jun 20260 · 0
Linda Bain Company insiderDirector · last 29 Jun 20260 · 0
Madduri Ravin Rao Company insiderDirector · last 29 Jun 20260 · 0
Michael W. Bonney Company insiderDirector · last 29 Jun 20260 · 0
Robert Azelby Company insiderDirector · last 29 Jun 20260 · 0
Robert Iannone Company insiderDirector · last 29 Jun 20260 · 0
Ryan Richardson Company insiderDirector · last 29 Jun 20260 · 0
William D. Young Company insiderDirector · last 29 Jun 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 2025-27.8%
Operating profit marginFY 2025 · to 31 Dec 2025-359%
Free cash flow marginFY 2025 · to 31 Dec 2025-401%
Return on capital employedFY 2025 · to 31 Dec 2025-52.5%
Interest coverFY 2025 · to 31 Dec 2025-7.38×
Research spendFY 2025 · to 31 Dec 2025156%
Share count trendFY 2025 · to 26 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$104.1M
Free cash flowFY 2025 · to 31 Dec 2025−$302.6M

Analyst forecasts

No analyst forecasts yet.